CG Oncology stock jumps 25% after pulling Phase 3 PIVOT-006 bladder cancer data into 1H 2026
New York, Jan 9, 2026, 11:52 EST — Regular session CG Oncology shares jumped on Friday after the company moved up the expected timing for late-stage trial results in bladder cancer. The stock was up 25.1% at $52.45 by 11:52 EST, versus Thursday’s close of $41.93, after trading between $41.63 and $52.64 on the day as volume topped 4.1 million shares.
